ARHGEF16

Across TCGA pan-cancer cohorts, ARHGEF16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF16 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ARHGEF16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF16 expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

COAD, LUAD, and CCRCC are the cancer types where ARHGEF16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	1.000	0.835	.032	12	view →
LUAD	DFS	Quartile	All	0.497	0.790	.016	5	view →
CCRCC	DFS	Median	II,III,IV	0.933	0.810	.034	3	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF16–COAD (DFS)

Open the COAD breakdown →